National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 67360 [2020-23373]
Download as PDF
<![CDATA[
67360
Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices
Dated: October 19, 2020.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–23444 Filed 10–21–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Prospective Grant of an Exclusive
Patent License: Development of a
Direct Ocular Administered
Formulation of Metformin for Use in
Therapeutic Treatment of Retinal
Degenerative Diseases in Humans
National Institutes of Health
AGENCY:
National Institutes of Health
BILLING CODE 4140–01–P
National Institutes of Health,
HHS.
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Emergency Awards: Rapid
Investigation of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS–CoV–2) and
Coronavirus Disease 2019 (COVID–19).
Date: November 20, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G41,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Tara Capece Scientific
Review Officer, Scientific Review Program,
Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers
Lane, Room 3G41, Rockville, MD 20852
,240–191–4281, capecet2@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 16, 2020.
Tyeshia M. Roberson,
Program Analyst. Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–23373 Filed 10–21–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:35 Oct 21, 2020
Jkt 253001
ACTION:
Notice.
The National Eye Institute, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice certain of the inventions
embodied in the Patents and Patent
Applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice to Connectyx Technologies
Holdings Group located in Boca Raton,
Florida.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before November 6, 2020 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Tedd Fenn, Senior
Technology Transfer Manager, NCI
Technology Transfer Center at
Telephone: (240) 276–5530 or Email:
Tedd.Fenn@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
U.S. provisional patent application
No. 62/899,899 and entitled, ‘‘Druggable
Targets to Treat Retinal Degeneration’’
filed September 13, 2019 (E–227–2017–
US–01); International Patent
Application No.: PCT/US2020/050540
and entitled, ‘‘Druggable Targets to
Treat Retinal Degeneration’’ filed
September 11, 2020 (E–227–2017–PCT–
02); and U.S. and foreign patent
applications claiming priority to the
aforementioned applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to rights to
develop, make use and sell, a direct
ocular-administered formulation of
metformin for use as therapeutics to
treat retinal degenerative diseases in
human.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
Metformin administration to Retinal
Pigment Epithelium (‘‘RPE’’) cells
derived from age-related macular
degeneration patients and to RPE cells
derived from Stargart’s-patients shows
reduced accumulations of disease
associated retinal deposits, suggesting
clinical treatment value for metformin
in retinal degenerative diseases.
Metformin is FDA approved for the
treatment of diabetes. No formulation of
metformin is available for direct ocular
use. Development of a direct ocular
delivery metformin formulation could
provide improved treatment effects for
retinal degenerative diseases, without
major systemic side effects.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: October 15, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2020–23386 Filed 10–21–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\22OCN1.SGM
22OCN1
]]>Agencies
[Federal Register Volume 85, Number 205 (Thursday, October 22, 2020)]
[Notices]
[Page 67360]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-23373]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Emergency Awards: Rapid
Investigation of Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19).
Date: November 20, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G41,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Tara Capece Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD
20852 ,240-191-4281, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 16, 2020.
Tyeshia M. Roberson,
Program Analyst. Office of Federal Advisory Committee Policy.
[FR Doc. 2020-23373 Filed 10-21-20; 8:45 am]
BILLING CODE 4140-01-P
